Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 Polymorphisms on 90-Day Ischemic Stroke Functional Outcome: A Novel Finding

Maguire, Jane; Thakkinstian, Ammarin; Levi, Christopher; Lincz, Lisa F.; Bisset, Linda; Sturm, Jonathan; Scott, Rodney J.; Whyte, Scott; Attia, John

doi:10.1016/j.jstrokecerebrovasdis.2009.10.011

Cited by 53 publications

(44 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9 For inclusion in the current study, cases had to have a diagnosis of ischemic stroke (defined by World Health Organization clinical criteria) classified by the Trial of Org 10172 in Acute Stroke Treatment system as large artery atherosclerotic, small vessel occlusion, or cardioembolic. 10,11 Exclusion criteria included age <18 years, diagnosis of hemorrhagic stroke or transient ischemic attack, and inability to undergo baseline brain imaging.…”

Section: Subjects For Aims 1 Andmentioning

confidence: 99%

“…In some patients, stroke severity was assessed using the National Institutes of Health Stroke Scale and later divided into minor (0-4), moderate (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15), moderate to severe (16)(17)(18)(19)(20), and severe (21-42) stroke as previously described. 9 Controls were obtained from the Hunter Community Study (HCS) that has previously been described in detail. 12 HCS recruited community-dwelling men and women aged 55 to 85 years from Newcastle, New South Wales, based on listings in the electoral roll between 2004 and 2007.…”

Section: Subjects For Aims 1 Andmentioning

confidence: 99%

“…At the time of recruitment, subjects were interviewed by research staff using standardized questionnaires. 9,12 Prior history of ever smoking, hypertension, diabetes mellitus, myocardial infarction, and atrial fibrillation was noted.…”

Section: Subjects For Aims 1 Andmentioning

confidence: 99%

“…Disability was assessed using the modified Rankin Scale (mRS) as previously described. 9,13 In brief, the mRS denotes 7 outcomes: 0, no symptoms; 1, no significant disability despite symptoms; 2, slight disability; 3, moderate disability; 4, moderately severe disability; 5, severe disability; and 6, death.…”

Section: Functional Outcomes In Stroke Cases For Aimmentioning

confidence: 99%

See 3 more Smart Citations

Plasma Angiopoietin-1 Is Lower After Ischemic Stroke and Associated With Major Disability But Not Stroke Incidence

Golledge

Clancy

Maguire

et al. 2014

Stroke

Self Cite

View full text Add to dashboard Cite

Background and Purpose— Studies in rodent models suggest that upregulating angiopoietin-1 (Angpt1) improves stroke outcomes. The aims of this study were to assess the association of plasma Angpt1 with stroke occurrence and outcome. Methods— Plasma Angpt1 was measured in 336 patients who had experienced a recent stroke and 321 healthy controls with no stroke history. Patients with stroke (n=285) were reassessed at 3 months and plasma Angpt1 concentration on admission compared between those with severe and minor disability as assessed by the modified Rankin scale. In a separate cohort of 4032 community-acquired older men prospectively followed for a minimum of 6 years, the association of plasma Angpt1 with stroke incidence was examined. Results— Median plasma Angpt1 was 3-fold lower in patients who had experienced a recent stroke (6.42, interquartile range, 4.26–9.53 compared with 17.36; interquartile range, 14.01–22.46 ng/mL; P <0.001) and remained associated with stroke after adjustment for other risk factors. Plasma Angpt1 concentrations on admission were lower in patients who had severe disability or died at 3 months (median, 5.52; interquartile range, 3.81–8.75 ng/mL for modified Rankin scale 3–6; n=91) compared with those with minor disability (median, 7.04; interquartile range, 4.75–9.92 ng/mL for modified Rankin scale 0–2; n=194), P =0.012, and remained negatively associated with severe disability or death after adjusting for other risk factors. Plasma Angpt1 was not predictive of stroke incidence in community-dwelling older men. Conclusions— Plasma Angpt1 concentrations are low after ischemic stroke particularly in patients with poor stroke outcomes at 3 months. Interventions effective at upregulating Angpt1 could potentially improve stroke outcomes.

show abstract

Section: Subjects For Aims 1 Andmentioning

confidence: 99%

Section: Subjects For Aims 1 Andmentioning

confidence: 99%

Section: Subjects For Aims 1 Andmentioning

confidence: 99%

Section: Functional Outcomes In Stroke Cases For Aimmentioning

confidence: 99%

See 2 more Smart Citations

Plasma Angiopoietin-1 Is Lower After Ischemic Stroke and Associated With Major Disability But Not Stroke Incidence

Golledge

Clancy

Maguire

et al. 2014

Stroke

Self Cite

View full text Add to dashboard Cite

show abstract

“…Research on the DNA damage and repair pathway [90] , cytochrome P450 [91] , COX-2 [92] , and endothelial nitric oxide synthase (eNOS) [21] in ischemic stroke has been reported; however, there was no reliable evidence of association, and further studies thus are required.…”

Section: Other Candidate Pathways and Genesmentioning

confidence: 99%

Genetics of stroke

Guo

Liu

2010

Acta Pharmacol Sin

View full text Add to dashboard Cite

Stroke is the second most common cause of death and the most common cause of disability in developed countries. Stroke is a multifactorial disease caused by a combination of environmental and genetic factors. Numerous epidemiologic studies have documented a significant genetic component in the occurrence of strokes. Genes encoding products involved in lipid metabolism, thrombosis, and inflammation are believed to be potential genetic factors for stroke. Although a large group of candidate genes have been studied, most of the epidemiological results are conflicting. Studies of stroke as a monogenic disease have made huge progress, and animal models serve as an indispensable tool to dissect the complex genetics of stroke. In the present review, we provide insight into the role of in vivo stroke models for the study of stroke genetics.

show abstract

Tenascin‐C is increased in atherothrombotic stroke patients and has an anti‐inflammatory effect in the human carotid artery

et al. 2014

Self Cite

View full text Add to dashboard Cite

Tenascin-C (Tn-C) is an endogenous ligand of toll-like receptor-4 (TLR-4); a key signalling molecule associated with chronic inflammatory conditions. Both Tn-C and TLR-4 are increased in unstable human atheroma, but their effects on local inflammatory conditions have not been investigated. The aim of the present study was to investigate the association and functional implications of Tn-C/TLR-4 signalling in large artery atherosclerotic stroke. Plasma Tn-C was measured by ELISA and found to be higher in recent stroke patients (n = 336; median 12.77 µg/mL, inter-quartile range 10.23-15.74 µg/mL) than in controls (n = 321; median 11.31 µg/mL, inter-quartile range 8.89-13.90 µg/mL), P < 0.001. Plasma Tn-C was also independently positively associated with stroke (odds ratio for highest Tn-C quartile 2.27, 95% confidence interval 1.37-3.76). Assessment of Tn-C associated chronic cytokine secretion was performed in vitro using paired, human, macroscopically disease matched, carotid atheroma tissue biopsies obtained from five patients undergoing carotid endarterectomy. A 4-day incubation with specific Tn-C blocking antibodies (Abs) increased secretion of TLR-4-associated cytokines, interleukin (IL)-8, IL-1β, tumour necrosis factor and C-C motif chemokine (CCL)3 and expression of TLR-4 in the tissue. These results suggest with Tn-C blockade another endogenous TLR-4 ligand upregulates TLR-4 expression and subsequent cytokine secretion. Titration of the Tn-C Abs also dose dependently increased secretion of IL-6, IL-8, IL-1β, and CCL3 in mixed, healthy, primary vascular cell culture. In summary, circulating concentrations of Tn-C are higher in patients with a recent history of atherosclerotic stroke and may play an anti-inflammatory role by reducing pro-inflammatory cytokine release from atheroma.

show abstract

Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 Polymorphisms on 90-Day Ischemic Stroke Functional Outcome: A Novel Finding

Cited by 53 publications

References 56 publications

Plasma Angiopoietin-1 Is Lower After Ischemic Stroke and Associated With Major Disability But Not Stroke Incidence

Plasma Angiopoietin-1 Is Lower After Ischemic Stroke and Associated With Major Disability But Not Stroke Incidence

Genetics of stroke

Tenascin‐C is increased in atherothrombotic stroke patients and has an anti‐inflammatory effect in the human carotid artery

Contact Info

Product

Resources

About